Total Doses Administered: All Vaccines 40,000 36,357 35,000 - PowerPoint PPT Presentation

Oct 17, 2023 •288 likes •334 views

Total Doses Administered: All Vaccines 40,000 36,357 35,000 31,440 34,315 30,000 25,000 20,000 15,000 15,578 10,000 5,000 0 February March April May 2019 2020 Data Source: VacTrAK (Alaskas Immunization Information System)

Total Doses Administered: All Vaccines 40,000 36,357 35,000 31,440 34,315 30,000 25,000 20,000 15,000 15,578 10,000 5,000 0 February March April May 2019 2020 Data Source: VacTrAK (Alaska’s Immunization Information System)
Total Doses Administered: All MMR Vaccine 3,000 2,500 2,196 1,915 2,000 1,500 1,467 1,000 829 500 0 February March April May 2019 2020 Data Source: VacTrAK (Alaska’s Immunization Information System)
Total Doses Administered: All Meningococcal Vaccine 1,000 919 873 900 800 776 700 600 500 400 300 200 245 100 0 February March April May 2019 2020 Data Source: VacTrAK (Alaska’s Immunization Information System)
Vaccine Shipments 30,000 25,000 22,820 20,000 15,000 10,000 7,171 5,000 0 February March April May 2019 2020 Data Source: VacTrAK (Alaska’s Immunization Information System)

Recommend

BIOE 301 Stimulate immunity without causing disease How are vaccines made?

Summary How do vaccines work? BIOE 301 Stimulate immunity without causing disease How are vaccines made? Non-infectious vaccines Live, attenuated bacterial or viral vaccines Carrier Vaccines Lecture Ten DNA Vaccines

413 views • 7 slides

Types of Vaccines Authorized to Administer Based upon APhA / NASPA Survey of State IZ Laws/ Rules

Pharmacist Administered Vaccines Types of Vaccines Authorized to Administer Based upon APhA / NASPA Survey of State IZ Laws/ Rules Any vaccine AL, AK, AZ*, AR, CA, CO, CT, Number of states / territories DC*, DE*, FL, GA*, HI, ID, IL, IN*, IA, KS,

411 views • 23 slides

BIOE 301 Lecture Ten Summary How do vaccines work? Stimulate immunity without causing

BIOE 301 Lecture Ten Summary How do vaccines work? Stimulate immunity without causing disease How are vaccines made? Non-infectious vaccines Live, attenuated bacterial or viral vaccines Carrier Vaccines DNA Vaccines

852 views • 38 slides

Explaining Operation Warp Speed Whats the goal? Operation Warp Speeds goal is to produce

Explaining Operation Warp Speed Whats the goal? Operation Warp Speeds goal is to produce and deliver 300 million doses of safe and efgective vaccines with the initial doses available by January 2021, as part of a broader strategy to

91 views • 5 slides

MEDI Examples VFC program changes will affect billing. Billing of VFC obtained vaccines

MEDI Examples VFC program changes will affect billing. Billing of VFC obtained vaccines administered to children who are Title XIX [19] eligible will not change. Providers must bill HFS or the participants managed care plan for private

547 views • 12 slides

GSK VACCINES IN 2011 Martin Andrews Senior Vice President Global Vaccines Centre of Excellence

GSK VACCINES IN 2011 Martin Andrews Senior Vice President Global Vaccines Centre of Excellence GSK Biologicals Todays agenda GSK GSK Global GSK vaccines: vaccines vaccines vaccines key growth pipeline market in 2011 drivers 2

699 views • 30 slides

Kratom Botanical that at low doses produce stimulation and at higher doses produce opioid effects

Kratom Botanical that at low doses produce stimulation and at higher doses produce opioid effects Potential for physical dependence and opioid-type effects/toxicities Marketed in Western countries and increasing use/toxicities being reported

593 views • 21 slides

COVID VACCINE INFORMATION FOR PHARMACIES October 22 nd , 2020 1 PHARMACIST IMPACT More than

10/26/2020 COVID VACCINE INFORMATION FOR PHARMACIES October 22 nd , 2020 1 PHARMACIST IMPACT More than 25% of annual influenza vaccinations are administered within pharmacies More than 50% of shingles vaccines are administered by

377 views • 24 slides

GSK VACCINES IN 2010 Thomas Breuer, MD, MSc Senior Vice President Head of Global Vaccines

GSK VACCINES IN 2010 Thomas Breuer, MD, MSc Senior Vice President Head of Global Vaccines Development GSK Biologicals Vaccines business characteristics Few global players and high barriers to entry Complex manufacturing Large

461 views • 33 slides

GSK VACCINES: KEY GROWTH DRIVERS Martin Andrews Senior Vice President, Global Vaccines Centre

GSK VACCINES: KEY GROWTH DRIVERS Martin Andrews Senior Vice President, Global Vaccines Centre of Excellence, GSK Biologicals Millions of children die from infectious diseases Many of these deaths are preventable By 2015 vaccines could reduce

447 views • 21 slides

Topics neo-antigens vs shared antigens as targets for vaccines new clinical settings

3/5/2018 The Evolving Role of Cancer Vaccines COL (ret) George E Peoples, MD, FACS Topics neo-antigens vs shared antigens as targets for vaccines new clinical settings (hence endpoints) for vaccine trials vaccines to improve

790 views • 12 slides

Access to Vaccines & the Econom ic Landscape Arizona VFAAC Meeting, 9-19-14 Phyllis Arthur

Access to Vaccines & the Econom ic Landscape Arizona VFAAC Meeting, 9-19-14 Phyllis Arthur Senior Director Vaccines, Immunotherapeutics & Diagnostics Policy parthur@bio.org I ntroduction Vaccines have had a dramatic impact on the

323 views • 19 slides

Progress in TB Product Development April 2013 Prasit Palittapongarnpim, M.D. TB Vaccines

Progress in TB Product Development April 2013 Prasit Palittapongarnpim, M.D. TB Vaccines Immunization Strategies- P: priming vaccine Viral vector vaccines, Recombinant (replace BCG), B: booster vaccine (after P or BCG protein vaccines,

821 views • 30 slides

Presented By: Vaccines obtained through the Vaccines For Children (VFC) program are limited to

Presented By: Vaccines obtained through the Vaccines For Children (VFC) program are limited to children age birth through 18 who have Title XIX (19) Medicaid eligibility on the date of service Children with Title XXI (21) - also referred

367 views • 19 slides

Update from the Vaccines and Related Biologics Products Advisory Committee (VRBPAC) Meeting of

Update from the Vaccines and Related Biologics Products Advisory Committee (VRBPAC) Meeting of October 22, 2020 Doran Fink, MD, PhD Deputy Director Clinical, Division of Vaccines and Related Products Applications, Office of Vaccines

349 views • 17 slides

Sanofi Pasteur: A partner in eradicating vaccine preventable diseases and improving access to

Sanofi Pasteur: A partner in eradicating vaccine preventable diseases and improving access to vaccines 1 2 Vaccines: the single most effective medical intervention Vaccines save lives Vaccines save money Millions of cases of

348 views • 10 slides

Pneumococcal conjugate vaccines Jerusha Naidoo, MBChB (UCT) Pfizer Vaccines

Pneumococcal conjugate vaccines Jerusha Naidoo, MBChB (UCT) Pfizer Vaccines jerusha.naidoo@pfizer.com Annual African Vaccinology Course: Developing Vaccinology Expertise for Africa OUTLINE S. pneumoniae, pneumococcal disease and

657 views • 62 slides

6/19/2019 Financial Disclosures To vaccinate or not? Efficacy and safety of vaccines, as wellas

6/19/2019 Financial Disclosures To vaccinate or not? Efficacy and safety of vaccines, as wellas Mark P. Walberg, PharmD, PhD, CTH discloses the followingrelationships: Previously employed as a paid speaker for Merck Vaccines the

712 views • 4 slides

Considerations for FDA Licensure vs. Emergency Use Authorization of COVID-19 Vaccines Doran

Considerations for FDA Licensure vs. Emergency Use Authorization of COVID-19 Vaccines Doran Fink, MD, PhD FDA/CBER Office of Vaccines Research and Review ACIP COVID-19 Meeting July 29, 2020 FDA Licensure Requirement for demonstration of

772 views • 8 slides

Evaluation of Doses, Risks, Vulnerabilities, and Consequences for Population and Environment

Evaluation of Doses, Risks, Vulnerabilities, and Consequences for Population and Environment Employing GIS Analysis Alexander Mahura 1 , Alexander Baklanov 1 , Olga Rigina 2 , Jens Havsk v Sorensen 1 , Rony Bergman 3 , Vladislav Golikov 4 ,

460 views • 14 slides

UNDERSTANDING HOMEOSTATIC CONTROL & ADAPTIVE RESPONSES TO LOW DOSES OF OXIDATIVE COMPOUNDS.

NRF2 IN REDOX BIOLOGY (SOT 2016) WEDNESDAY 16 TH MARCH UNDERSTANDING HOMEOSTATIC CONTROL & ADAPTIVE RESPONSES TO LOW DOSES OF OXIDATIVE COMPOUNDS. SARAH COOPER SAFETY & ENVIRONMENTAL ASSURANCE CENTRE SEAC 1 Unilever Information:

223 views • 9 slides

Summary of doses and approach: Wetland scenario A Bollhfer, C Doering # , B Ryan &

www.environment.gov.au/ssd Summary of doses and approach: Wetland scenario A Bollhfer*, C Doering # , B Ryan & * Environmental Research Institute of the Supervising Scientist (eriss), Darwin, NT, Australia # Australian Radiation Protection

199 views • 5 slides

PATIENT AND STAFF DOSES IN INTERVENTIONAL NEURORADIOLOGY Doan Bor 1 Ph.D, Saruhan ekirge 2 ,

PATIENT AND STAFF DOSES IN INTERVENTIONAL NEURORADIOLOGY Doan Bor 1 Ph.D, Saruhan ekirge 2 , M.D, Trkay Toklu 1 M.Sc., Turan Olar 1 M.Sc., Miyase Glay 1 M.Sc. , Elif nal 1 M.Sc., Barbaros il 2 M.D 1:Ankara University Faculty of

613 views • 36 slides

COVID-19 and You HB-481 Relief Late June 2020 Received $2,022,475.68 total Cares Act

COVID-19 and You HB-481 Relief Late June 2020 Received $2,022,475.68 total Cares Act grant fund distribution is pursuant to HB-481 Considered and audited as a federal grant Administered through the Ohio Office of Budget &

515 views • 12 slides